D. Reisman

D. Reisman, E. A. Thompson, W. Bresnahan, 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells.

V. Rotter, D. Reisman, 1989, Oncogene.

An EBNA-negative, EBV-genome-positive human lymphoblast cell line in which superinfecting EBV DNA is not maintained.

D. Reisman, B. Sugden, 1984, Virology.

Loss of heterozygosity and p53 expression in Pterygium.

Gary Lu, D. Reisman, David Reisman, 2004, Cancer letters.

Optimization for Testing the Sensitivity and Specificity of Antibodies to Brg1

D. Reisman, S. Marquez, Li Lu, 2014 .

A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components

D. Reisman, J. Yates, B. Sugden, 1985, Molecular and cellular biology.

MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition.

Y. Dou, Lihua Jin, D. Reisman, 2016, Cell reports.

A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth

J. Lee, D. Reisman, Peisheng Xu, 2016, Oncotarget.

Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation

D. Reisman, S. Marquez, K. Thompson, 2015, Front. Oncol..

Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

D. Reisman, B. Kahali, A. Aponick, 2014, Carcinogenesis.

Identifying targets for the restoration and reactivation of BRM

D. Reisman, B. Kahali, S. Marquez, 2014, Oncogene.

Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy

D. Reisman, C. Rogers, S. Gramling, 2011, Oncogene.

Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53

W. Loging, D. Reisman, 1999, Oncogene.

Induction of functional Brm protein from Brm knockout mice

D. Reisman, S. Marquez, K. Thompson, 2015, Oncoscience.

Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1arrest associated with induction of p16ink4a and activation of RB

Matthew W. Strobeck, B. Weissman, D. Reisman, 2002, Oncogene.

trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1

D. Reisman, B. Sugden, D. Reisman, 1986, Molecular and cellular biology.

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

D. Reisman, J. Yates, B. Sugden, 1984, Proceedings of the National Academy of Sciences of the United States of America.

c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.

V. Rotter, D. Reisman, J. Beamon, 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors

D. Reisman, J. Beamon, E. Balint, 1994, Molecular and cellular biology.

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome

A. Azad, G. Darling, Geoffrey Liu, 2017, Oncotarget.

Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development

D. Reisman, Li Lu, S. Gramling, 2016, Oncoscience.

Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers

M. Tsao, F. Shepherd, A. Azad, 2014, Cancer medicine.

Targeted knockout of BRG1 potentiates lung cancer development.

D. Metzger, D. Reisman, A. Palanca, 2008, Cancer research.

Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies

Weidong Wang, B. Weissman, D. Reisman, 2001, Journal of cellular physiology.

Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk

M. Tsao, F. Shepherd, A. Azad, 2011, Oncogene.

Inducible expression of Mad accelerates growth arrest of serum deprived human glioblastoma cells

D. Reisman, Baishali Roy, David Reisman, 1995, Cell Biology International.

Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene

D. Reisman, S. Durland-Busbice, 2002, Leukemia.

Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer

Sandya Liyanarachchi, David Jarjoura, Christoph Plass, 2007, PLoS medicine.

Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter

D. Reisman, K. Boggs, 2006, Oncogene.

Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin

J. Lakins, V. Weaver, D. Reisman, 2014, Oncogene.

Compromised HOXA5 function can limit p53 expression in human breast tumours

S. Sukumar, E. Jaffee, V. Raman, 2000, Nature.

Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.

R. Gilbert, B. O'Sullivan, A. Azad, 2013, Carcinogenesis.

Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells.

D. Reisman, E. Balint, 1996, Cancer research.

Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis

Geoffrey Liu, Wei Xu, D. Reisman, 2019, Molecular carcinogenesis.

Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor

D. Reisman, Anne H. Moxley, 2020, Cell biochemistry and function.

HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance.

J. Lee, D. Reisman, Y. Iwakura, 2018, Cancer research.

AP-1 DNA binding activity induced by hyperosmolality in the rat hypothalamic supraoptic and paraventricular nuclei.

D. Reisman, J. Buggy, Z. Ying, 1996, Brain research. Molecular brain research.

Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas.

Saraswati Sukumar, Pang-Kuo Lo, J. Lee, 2013, Experimental and molecular pathology.

Transcriptional Activation of the p53 Tumor Suppressor Gene Provides a Rapid Protective Mechanism against DNA Damage during S-phase of the Cell Cycle

D. Reisman, 2013 .

Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.

D. Reisman, S. Thomas, 2006, Cancer letters.

Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.

W. Loging, D. Reisman, Loging Wt, 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Rapid liver enlargement and hepatic failure secondary to radiographic occult tumor invasion: two case reports and review of the literature

D. Reisman, R. Shifrin, M. Murphy, 2012, Journal of Medical Case Reports.

Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1.

V. Rotter, D. Reisman, M. Greenberg, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression

Matthew W. Strobeck, W. Funkhouser, M. Yaniv, 2002, Oncogene.

Transcriptional regulation of the p53 tumor suppressor gene.

W. Loging, D. Reisman, 1998, Seminars in cancer biology.

A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells.

V. Rotter, W. Loging, D. Reisman, 1996, Genomics.

An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer

D. Reisman, Harini Bejjanki, R. Bishnoi, 2017, Applied Cancer Research.

Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle

D. Reisman, A. Polson, P. Takahashi, 2011, Apoptosis.

1 p 53 Response to DNA Damage during S-Phase

D. Reisman, A. Polson, P. Takahashi, 2010 .

Nuclear factor‐1 (NF‐1) binds to multiple sites within the transcriptional enhancer of Moloney Murine Leukemia virus

D. Reisman, 1990, FEBS letters.

HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.

Sheng Feng, Yvonne Hui, Saraswati Sukumar, 2015, Cancer research.

Transcriptional Repression of p53 by Human T-cell Leukemia Virus Type I Tax Protein (*)

D. Reisman, H. Giebler, J. Nyborg, 1995, The Journal of Biological Chemistry.

BRM polymorphisms, pancreatic cancer risk and survival

S. Gallinger, Geoffrey Liu, M. Cotterchio, 2016, International journal of cancer.

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

ChIP (chromatin immunoprecipitation) analysis demonstrates co‐ordinated binding of two transcription factors to the promoter of the p53 tumour‐suppressor gene

D. Reisman, A. Polson, P. Takahashi, 2010, Cell biology international.

RBP‐Jκ binds to and represses transcription of the p53 tumor suppressor gene

D. Reisman, K. Boggs, Brystol L Henderson, 2009, Cell biology international.

C/EBPβ Participates in Regulating Transcription of the p53 Gene in Response to Mitogen Stimulation*

D. Reisman, K. Boggs, 2007, Journal of Biological Chemistry.

The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene.

V. Rotter, D. Reisman, 1993, Nucleic acids research.

GP 88 ( Progranulin ) : A novel tissue and circulating biomarker for non-small cell lung carcinoma

M. Edelman, D. Reisman, P. Bejarano, 2014 .

Surgical resection for metastatic non-small cell lung cancer to the pancreas.

Richard K. J. Brown, D. Reisman, Rachel L Wilson, 2009, Lung cancer.

Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.

D. Reisman, Harini Bejjanki, R. Bishnoi, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Carcinogenesis

Wei Xu, D. Reisman, N. Leighl, 2019 .

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.

R. Gilbert, B. O'Sullivan, A. Azad, 2013, Carcinogenesis.

GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.

M. Edelman, D. Reisman, P. Bejarano, 2014, Human pathology.

Targeted knockout of BRG1 potentiates lung cancer development.

D. Metzger, D. Reisman, A. Palanca, 2008, Cancer research.

HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance.

J. Lee, D. Reisman, Y. Iwakura, 2018, Cancer research.

Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas.

Pang-Kuo Lo, J. Lee, S. Sukumar, 2013, Experimental and molecular pathology.

The WRAP53α gene undergoes p53 tumor suppressor-dependent transcriptional regulation in response to DNA Damage

D. Reisman, Anne H. Moxley, 2021, Gene Reports.